The group looks like the gene therapy contender to beat, but that is not saying much.
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
The Bristol-Myers Squibb and Amicus drugs face approval decisions next week.